CDSCO panel recommends restricted emergency use of anti-COVID pill Molnupiravir
The Hindu
The pill is intended to be taken twice a day for five days by people at home with mild to moderate COVID-19.
An expert panel of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-COVID pill Molnupiravir for restricted emergency use for the treatment of COVID-19 patients in the country, official sources said.
The emergency use of the drug will be for adult COVID-19 patients with SpO2 93% and who have a high risk of progression of the disease including hospitalisation or death subject to certain conditions, they added.
Dr Reddy’s Laboratories in consortium with Cipla, Mylan, Torrent, Emcure and Sun Pharma had presented their proposal for approval of Molnupiravir 200mg capsules for approval in the emergency situation along with various supporting documents including clinical data in the country.

India’s gem and jewellery industry continues to demonstrate remarkable resilience and a spirit of innovation, said Kirit Bhansali, chairman of the Gem and Jewellery Export Promotion Council (GJEPC), at the inauguration of the 4th edition of IIJS Bharat-Tritiya 2026 at Bengaluru International Exhibition Centre (BIEC) here on Saturday, March 21.












